Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10015691HBVENSG00000134460.19protein_codingIL2RANoNo3559P01589
Q5W005
TVIS10026184HBVENSG00000134460.19protein_codingIL2RANoNo3559P01589
Q5W005
TVIS30011403HIVENSG00000134460.19protein_codingIL2RANoNo3559P01589
Q5W005
TVIS30004372HIVENSG00000134460.19protein_codingIL2RANoNo3559P01589
Q5W005
TVIS30010128HIVENSG00000134460.19protein_codingIL2RANoNo3559P01589
Q5W005
TVIS20032371HPVENSG00000134460.19protein_codingIL2RANoNo3559P01589
Q5W005
TVIS20040966HPVENSG00000134460.19protein_codingIL2RANoNo3559P01589
Q5W005
TCGA Plot Options
Drug Information
GeneIL2RA
DrugBank IDDB00004
Drug NameDenileukin diftitox
Target IDBE0000658
UniProt IDP01589
Regulation Typebinder
PubMed IDs2786749; 3124610; 18684057; 17187516
CitationsKiyokawa T, Shirono K, Hattori T, Nishimura H, Yamaguchi K, Nichols JC, Strom TB, Murphy JR, Takatsuki K: Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia. Cancer Res. 1989 Jul 15;49(14):4042-6.@@Murphy JR, Kelley VE, Strom TB: Interleukin 2 toxin: a step toward selective immunomodulation. Am J Kidney Dis. 1988 Feb;11(2):159-62.@@Duvic M, Talpur R: Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69. doi: 10.2217/14796694.4.4.457.@@Turturro F: Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7.
GroupsApproved; Investigational
Direct ClassificationPeptides
SMILES
Pathways
PharmGKBPA164750594
ChEMBLCHEMBL1201550